Evidence map›Paper›PMID 35572559›Full record

ArticleFrontiers in immunology2022

Establishment of a lncRNA-Based Prognostic Gene Signature Associated With Altered Immune Responses in HCC.

Xiawei Li, Zhiqian Zhang, Mingcheng Liu, Xing Fu, Jun A, Guoan Chen, Shian Wu, Jin-Tang Dong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. LncRNAInternational journal of biological sciences · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiawei LiDepartment of Genetics and Cell Biology, College of Life Sciences, Nankai University, Tianjin, China.
Zhiqian ZhangLaboratory Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Mingcheng LiuLaboratory Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Xing FuLaboratory Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Jun ALaboratory Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Guoan ChenLaboratory Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Shian WuDepartment of Genetics and Cell Biology, College of Life Sciences, Nankai University, Tianjin, China.
Jin-Tang DongLaboratory Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Southern University of Science and Technology · CNNankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy with higher mortality, and means are urgently needed to improve the prognosis. T cell exclusion (TCE) plays a pivotal role in immune evasion, and lncRNAs represent a large group of tumor development and progression modulators. Using the TCGA HCC dataset (n=374), we identified 2752 differentially expressed and 702 TCE-associated lncRNAs, of which 336 were in both groups. As identified using the univariate Cox regression analysis, those associated with overall survival (OS) were subjected to the LASSO-COX regression analysis to develop a prognosis signature. The model, which consisted of 11 lncRNAs and was named 11LNCPS for 11-lncRNA prognosis signature, was validated and performed better than two previous models. In addition to OS and TCE, higher 11LNCPS scores had a significant correlation with reduced infiltrations of CD8+ T cells and dendritic cells (DCs) and decreased infiltrations of Th1, Th2, and pro B cells. As expected, these infiltration alterations were significantly associated with worse OS in HCC. Analysis of published data indicates that HCCs with higher 11LNCPS scores were transcriptomically similar to those that responded better to PDL1 inhibitor. Of the 11LNCPS lncRNAs,

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRNA, Long NoncodingBiomarkers, TumorHumansImmunityPrognosisBiomarkers, TumorRNA, Long NoncodingAC116025.2hepatocellular carcinoma (HCC)LINC01134lncRNAprognosisT cell exclusion

Identifiers

PMID35572559
PMCPMC9097819
OpenAlexW4225000356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.